|Articles|October 14, 2022
- Applied Clinical Trials-10-01-2022
- Volume 31
- Issue 10
Applied Clinical Trials October 2022 Issue (PDF)
Advertisement
Articles in this issue
over 3 years ago
Managing Biospecimens in Cell and Gene Therapy Trialsover 3 years ago
The Risk-Reward Proposition for CGT Clinical Trialsover 3 years ago
Philadelphia Shines in Cell and Gene Therapy Research Pursuitsover 3 years ago
Survey Investigates Backup Solution Adoption for ePRO Systemsover 3 years ago
Scientists Don’t Ever Stop Sciencingalmost 4 years ago
Key Clinical Trial Industry Themes Post-COVIDAdvertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
NEJM Retracts Tavneos Trial Paper as FDA, EMA Both Move to Pull Amgen Drug From Market
2
ACT Brief: Tavneos Trial Integrity Issues, Selective Safety Data Regulatory Pathways, and FDA PreCheck Program Launch
3
ACT Brief: Real-Time Trial Infrastructure Gaps, Built-In Data Security, and AI-Enabled CDMO Value
4
Real-Time Clinical Trials: What the FDA's Push Toward Continuous Oversight Means for Sponsors
5